The use of central nervous system active drugs during pregnancy

Pharmaceuticals

Volumn 6, Issue 10, 2013, Pages 1221-1286

  Källén, Bengt ^a   Borg, Natalia ^b   Reis, Margareta ^c  

^a UNIVERSITY OF LUND   (Sweden)

^b NATIONAL BOARD OF HEALTH AND WELFARE   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Antidepressants; CNS active drugs; Congenital malformations; Hypnotics; Neonatal morbidity; Opioids; Psychostimulants; Sedatives

Indexed keywords

EID: 84885641016     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph6101221     Document Type: Review

References (174)

1. Lenz, W. Kindlische missbildungen nach medikament-einnahme während der gravidität? Dtsch. Med. Wochenschr 1961, 37, 1863-1866.
2. McBride, W.G. Thalidomide and congenital abnormalities. Lancet 1961, 2, 1358.
3. McBride, W.G. The teratogenic effect of imipramine. Teratology 1972, 5, 262.
4. Safra, M.J.; Oakley, G.P. Valium: An oral cleft teratogen? Cleft. Palate J. 1976, 13, 198-200.
5. Meadow, S.R. Congenital anomalies and anticonvulsant drugs. Proc. Roy. Soc. Med. 1968, 63, 12-49.
6. National Board of Health and Welfare. Centre for Epidemiology. The Swedish Medical Birth Register-A summary of content and quality. 2003. Available online: http://www.socialstyrelsen.se/Publikationer2003/2003-112-3 (accessed on 10 September 2013).
7. National Board of Health and Welfare. Centre for Epidemiology. Registration of congenital malformations in Swedish health registers. 2004. Available online: http://www.socialstyrelsen.se/Publikationer2004/2004-112-1 (accessed on 10 September 2013).
8. Källén, B. Drugs during Pregnancy; Nova Biomedical Books: New York, NY, USA, 2009; pp. 312-318, 332, 357, 363.
9. Wettermark, B.; Hammar, N.; Fored, C.M.; Leimanis, A.; Otterblad Olausson, P.; Bergman, U.; Persson, I.; Sundström, A.; Westerholm, B.; Rosén, M. The new Swedish prescribed drug register-Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol. Drug Safety 2007, 16, 726-735.
10. Källén, B. Birth weight for gestational age standard based on data in the Swedish Medical Birth Register, 1985-1989. Eur. J. Epidemiol. 1995, 11, 601-606.
11. Saxén, L. Associations between oral clefts and drugs taken during pregnancy. Int. J. Epidemiol. 1975, 4, 37-44.
12. Rothman, K.J.; Fyler, D.C.; Goldblatt, A.; Kreidberg, M.B. Exogenous hormones and other drug exposures of children with congenital heart disease. Am. J. Epidemiol. 1979, 109, 433-439.
13. Bracken, E.; Holford, T. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet. Gynecol. 1981, 58, 336-344.
14. Golden N.L.; King, K.C.; Sokol, R.J. Propoxyphene and acetaminophen. Possible effects on the fetus. Clin. Pediatr. 1982, 21, 752-754.
15. Heinonen, O.P.; Slone, D.; Shapiro, S. Birth Defects and Drugs in Pregnancy; Publishing Sciences Group, Inc.: Littleton, CO, USA, 1977; pp. 293, 352.
16. Nezvalová, K.; Spigset, O.; Nordeng, H. Effect of codeine on pregnancy outcome: Results from a large population-based cohort study. Eur. J. Clin. Pharmacol. 2011, 67, 1253-1261.
17. Broussard, C.S.; Rasmussen, S.A.; Reefhuis, J.; Friedman, J.M.; Jann, M.W.; Riehle-Colarusso, T.; Honein, M.A. National Birth Defects Prevention Study. Maternal treatment with opioid analgesics and risk for birth defects. Am. J. Obst. Gynecol. 2011, 204, 314. e1-314. e11.
18. Bloor, M.; Paech, M.J.; Kaye, R. Tramadol in pregnancy and lactation. Int. J. Obst. Anaesth. 2012, 21, 163-167.
19. Gouraud, A.; Beyens, M.N.; Boyer, M.; Carlier, P.; Thompson, M.A.; Garayt, C.; Bernard, N.; Viak, T. First trimester exposure to tramadol: A prospective comparative study. Fundam. Clin. Pharmacol. 2010, 24 (Suppl.1), 90 (Abstract No 435).
20. Fajemirokun-Odudeyi, O.; Sinha, C.; Tutty S.; Pairaudeau P.; Armstrong D.; Phillips T.; Lindow, S.W. Pregnancy outcome in women who use opiates. Eur. J. Obst. Gynecol. Reprod. Biol. 2006, 126, 170-175.
21. Finnegan, L.P.; Connaughton, J.F.; Kron, R.E.; Emich, J.P. Neonatal abstinence syndrome: Assessment and management. Addict. Dis. 1975, 2, 141-158.
22. Hartenstein, S.; Proquitte, H.; Bauer, S.; Bamberg. C.; Roehr, C.C. Neonatal abstinence syndrome (NAS) after intrauterine exposure to tramadol. J. Perinat. Med. 2010, 38, 695-696.
23. Ente. G.; Mehra, M.C. Neonatal withdrawal from propoxyphene hydrochloride. N. Y. State J. Med. 1978, 78, 2084-2085.
24. Khan, K.; Chang, J. Neonatal abstinence syndrome due to codeine. Arch. Dis. Child Fetal Neonatal. Ed. 1997, 76, F59-F60.
25. Källén, B.; Reis, M. Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. J. Clin. Psychopharm. 2012, 12, 608-614.
26. Janz, D.; Fuchs, U. Sind antiepileptische Medikamente während der Schwangerschaft schädlich? Deutch. Med. Wschr. 1964, 89, 241-243.
27. Adab, N.; Tudor Smith, C.; Vinten, J.; Williamson, P.R.; Winterbottom, J.B. Common antiepileptic drugs in pregnancy in women with epilepsy (Review). Cochrane Libr. 2008, 2008, CD004848.
28. Reimers, A.; Brodtkorb, E. Second-generation antiepileptic drugs and pregnancy: A guide for clinicians. Exp. Rev. Neurother. 2012, 12, 707-717.
29. Robert, E.; Guibaud, P. Maternal valproic acid and congenital neural tube defects. Lancet 1982, 320, 937.
30. Dansky, L.V.; Finnell, R.H. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiologic and experimental findings spanning three decades. 2: Human studies. Reprod. Toxicol. 1993, 5, 301-335.
31. Meador, K.; Reynolds, M.W.; Crean, S.; Fahrbach, K.; Probst, C. Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008, 81, 1-13.
32. Béthenod, M.; Frédérich, A. Les enfants de antiépileptiques. Pédiatrie 1975, 30, 227-248.
33. Hanson, J.W.; Myrianthopoulos, N.C.; Sedgwick Harvey, M.A.; Smith, D.W. Risks to the offspring of women treated with hydantoid anticonvulsants, with emphasis on the fetal hydantoin syndrome. J. Pediatr. 1976, 89, 662-668.
34. Morrow, J.; Russell, A.; Guthrie, E.; Parsons, L.; Robertson, I.; Waddell, R.; Irwin, B.; McGivern, R.C.; Morrison, P.J.; Craig, J. Malformation risks of antiepileptic drugs in pregnancy: A prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psych. 2006, 77, 193-198.
35. Wyszynski, D.F.; Nambisan, M.; Surve, T.; Alsdord, R.M.; Smith, C.R.; Holmes, L.B.; Antiepileptic drug pregnancy registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005, 64, 961-965.
36. Hernández-Diaz, S.; Smith, C.R.; Shen, A.; Mittendorf, R.; Hauser, W.A.; Yerby, M.; Holmes, L.B.; North American AED pregnancy register. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012, 78, 1692-1699.
37. Vajda, F.J.; Grahan, J.; Roten, A.; Lander, C.M.; O'Brien, T.J.; Eadie, M. Teratogenicity of the newer antiepileptic drugs-The Australian experience. J. Clin. Neurosci. 2012, 19, 57-59.
38. Tomson, T.; Battino, D.; Bonizzoni, E.; Craig, J.; Lindhout, D.; Sabers, A.; Penucca, E.; Vajda, F.; EURAP Study Group. Dose-dependent risk of malformations with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011, 1, 609-617.
39. Montouris, G. Gabapentin exposure in human pregnancy: Results from the Gabapentin Pregnancy Registry. Epilepsy Behav. 2003, 4, 310-317.
40. Cunnington, M.C.; Well, J.G.; Messerheimer, J.A.; Ferber, S.; Yerby, M.; Tennis, P. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 2011, 24, 1817-1823.
41. Pennell, P.B.; Klein, A.M.; Browning, M.; Baker, G.A.; Clayton-Smith, J.; Kalayjian, L.A.; Liporace, J.D.; Privitera, M.; Crawford, T.; Loring, D.W.; et al. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav. 2012, 24, 449-456.
42. Mølgaard-Nielsen, D.; Hviid, A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011, 305, 1996-2002.
43. Velby, G.; Daltveit, A.K.; Engelsen, B.A.; Gilhus, N.E. Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 2009, 50, 2130-2139.
44. Wide, K.; Winbladh, B.; Källén, B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: A nation-wide, populationbased register study. Acta Paediatr. 2004, 93, 174-176.
45. Artama, M.; Ritvanen, A.; Gissler, M.; Isojärvi, J.; Auvinen, A. Congenital structural anomalies in offspring of women with epilepsy-A population-based cohort study in Finland. Int. J. Epidemiol. 2006, 35, 280-287.
46. Holmes, L.B.; Baldwin, E.J.; Smith, C.R.; Habecker, E.; Glassman. L.; Wong, S.L.; Wyszynski, D.F. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008, 70, 2152-2158.
47. Koo, J.; Zevras, A. Antiepileptic drugs (AEDs) during pregnancy and risk of congenital jaw and oral malformation. Oral. Dis. 2013, 19, 712-720.
48. Dolk, H.; Jentink, J.; Loane, M.; de-Jong-van den Berg, L.T.; EUROCAT Antiepileptic Drug Working Group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008, 71, 714-722.
49. Ornoy, A.; Zvi, N.; Amon, J.; Wainberg, R.; Shechtman, S.; Diav-Citrin, O. The outcome of pregnancy following topiramate treatment: A study on 52 pregnancies. Reprod. Tox. 2008, 25, 388-389.
50. Hunt, S.; Russell, A.; Smithson, W.H.; Parsons, L.; Robertson, I.; Waddell, R.; Irwin, B.; Morrison, P.J.; Morrow, J.; Craig, J.; et al. Topiramate in pregnancy: Preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008, 22, 272-276.
51. Green, M.W.; Seeger, J.D.; Peterson, C.; Bhattacharyya, A. Utilization of topiramate during pregnancy and risk of birth defects. Headache 2012, 52, 1070-1084.
52. Margulis, A.V.; Mitchell, A.A.; Gilboa, S.M.; Werler, M.M.; Mittleman, M.A.; Glynn, R.J.; Hernández-Diaz, S.; National Birth Defects Prevention Study. Use of topiramate in preganncy and risk of oral clefts. Am. J. Obst. Gynecol. 2012, 207, 405. e1-405. e7.
53. Longo, B.; Forinash, A.B.; Murphy, J.A. Leveteracetam use in pregnancy. Ann. Pharmacother. 2009, 43, 1692-1695.
54. Mawhinney, E.; Craig, J.; Morrow, J.; Russel, A.; Smithson, W.H.; Parsons, L.; Morrison, P.J.; Liggan, B.; Inwin, B.; et al. Leveteracetam in pregnancy: Results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2012, 80, 400-405.
55. Bossi, L. Fetal Effects of Anticonvulsants. In Antiepileptic Drug Therapy in Pediatrics; Morselli, P.L., Pipenger, C.E., Oenry, I.K., Eds.; Raven Press: New York, NY, USA. 1983; pp. 37-64.
56. Wide, K.; Winbladh, B.; Thomson, T.; Källén, B. Body dimensions of infants exposed to antiepileptic drugs in utero: Observations spanning 25 years. Epilepsia 2000, 41, 854-861.
57. Almgren, M.; Källén, B.; Lavebratt, C. Population-based study of antiepileptic drug exposure in utero-Influence on head circumference in newborns. Seizure 2009, 18, 672-675.
58. Nora, J.J.; Nora, A.H.; Way, G.L. Cardiovascular maldevelopment associated with maternal exposure to amantadine. Lancet 1975, 306, 607.
59. Pandit, P.B.; Chitayat, D.; Jefferies, A.L.; Landes, A.; Qamar, I.U.; Koren, G. Tibial hemimelia and tetralogy of Fallot associated with first trimester exposure to amantadine. Reprod. Toxicol. 1994, 8, 89-92.
60. Golbe, L.I. Parkinson's disease and pregnancy. Neurology 1987, 37, 1235-1249.
61. Krupp, P.; Monka, C. Bromocriptine in pregnancy: Safety aspects. Klin. Wochenschr. 1987, 65, 823-827.
62. Ricci, E.; Parazzini, F.; Molta, T.; Ferrari, C.I.; Clavenna, A.; Rocchi, F.; Gangi, E.; Paracchi, S.; Gasperi, M.; Lavessari, M.; et al. Pregnancy outcome after cabgergoline treatment in early weeks of gestation. Reprod. Toxicol. 2002, 16, 791-793.
63. Colao, A.; Abs, R.; González Bárcena, D.G.; Chanson, P.; Paulus, W.; Kleinberg, D.L. Pregnancy outcomes following cabergoline treatment: Extended results from a 12-year observational study. Clin. Endocrinol. 2008, 66, 66-71.
64. Lebbe, M.; Huvinont, C.; Bernard, P.; Maiter, D. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin. Endocrinol. 2010, 73, 236-242.
65. Stalldecker, G.; Mallea-Gil, M.S.; Guitelman, M.; Alfieri, A.; Ballarino, M.C.; Boero, L.; Chervin, A.; Danilowicz, K.; Diez, S.; Fainstein-Day, P.; et al. Effects of cabergoline on pregnancy and embryo-fetal development: Retrospective study on 103 pregnancies and a review of the literature. Pituitary 2010, 13, 345-350.
66. Kranick, S.M.; Mowry, E.M.; Colcher, A.; Horn, S.; Golbe, L.I. Movement disorders and pregnancy: A review of the literature. Mov. Disord. 2010, 25, 665-671.
67. Gentile, S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr. Bull. 2010, 36, 518-544.
68. Moriarity, A.J.; Nance, M.R. Trifluoperazine and pregnancy. Can. Med. Assoc. J. 1963, 88, 375-376.
69. Bodén, R.; Lundgren, M.; Brandt, L.; Reutfors, J.; Andersen, M.; Kieler, H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: Population based cohort study. BMJ 2012, 345, e7085.
70. Anderka, M.; Mitchell, A.A.; Louik, C.; Werler, M.M.; Hernández-Diaz, S.; Rasmussen, S.A.; National Birth Defects Prevention Study. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth. Defects Res. (Part A) 2012, 94, 22-30.
71. Bodén, R.; Lundgren, M.; Brandt, L.; Reutfors, J.; Kieler, H. Antipsychotics during pregnancy: Relation to fetal and maternal metabolic effects. Arch. Gen. Psychiatry 2012, 69, 715-721.
72. Weinstein, M.R. The international register of lithium babies. Drug. Inf. 1976, 10, 94-100.
73. Warkany, J. Teratogen update: Lithium. Teratology 1988, 35, 593-596.
74. Källén, B. Comments on teratogen update: Lithium. Teratology 1988, 38, 597.
75. Zalzstein, E.; Koren, G.; Einarson, T.; Freedom, R.M. A case-control study on the association between first trimester exposure to lithium and Ebstein's anomaly. Am. J. Cardiol. 1990, 65, 817-818.
76. Jacobsson, S.J.; Jones, K.; Johnson, K.; Ceolin, L.; Kaur, P.; Sahn, D.; Donnenfeld, A.E.; Rieder, M.; Santelli, R.; Smythe, J.; et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992, 339, 530-533.
77. Yacobi, S.; Ornoy, A. Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review. Isr. Psychiatry Rel. Sci. 2008, 45, 95-106.
78. Cohen, L.S.; Friedman, J.M.; Jefferson, J.W.; Johnson, E.M.; Weiner, M.L. A reevaluation of risk of in utero exposure to lithium. JAMA 1994, 271, 146-150.
79. Gentile, S. Lithium in pregnancy: The need to treat, the duty to ensure safety. Expert Opin. Drug. Saf. 2012, 11, 425-437.
80. Crombie, D.L.; Pinsent, R.J.F.H.; Slaer, B.C.; Fleming, D.; Cross, R.W. Teratogenic drugs-RCGP survey. BMJ 1970, 4, 178-179.
81. Richards, I.D.G. A Retrospective Enquiry into Possible Teratogenic Effects of Drugs in Pregnancy. In Drugs and Fetal Development; Klingberg, M.A., Abramovici, A., Chemke, J., Eds.; Plenum Press: New York, NY, USA; 1972; pp. 441-445.
82. Saxén, I.; Saxén, L. Association between maternal intake of diazepam and oral clefts. Lancet 1975, 306, 498.
83. Laegreid, L.; Olegård. R.; Conradi, N.; Hagberg, G.; Wahlström, J.; Abrahamsson, L. Congenital malformations and maternal consumtion of benzodiazepines: A case-control study. Dev. Med. Child Neurol. 1990, 32, 432-441.
84. Weber, I.W.D. Benzodiazepines in pregnancy-Academical debate or teratogenic risk? Biol. Res. Pregnancy 1985, 6, 151-167.
85. Dolovich, L.R.; Addis, A.; Vaillancourt, J.M.R.; Power, J.D.B.; Koren, G. Benzodiazepine use in pregnancy and major malformations or oral clefts: Meta-analysis of cohort or case-control studies. BMJ 1998, 317, 839-843.
86. Norstedt Wikner, B.; Stiller, C.-O.; Bergman, U.; Asker, C.; Källén, B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: Neonatal outcome and congenital malformations. Pharmacoepidemiol. Drug. Saf. 2007, 16, 1203-1210.
87. Bonnot, O.; Vollset, S.E.; Godet, P.F.; D'Amato, T.; Robert, E. In utero exposure to benzodiazepine. Is there a risk for anal atresia with lorazepam? Encéphale 2003, 29, 553-559.
88. Norstedt Wikner, B.; Källén, B. Are hypnotic benzodiazepine receptor agonists teratogenic in humans? J. Clin. Psychopharmacol. 2011, 31, 356-358.
89. McElhatton, P.R. The effects of benzodiazepine use during pregnancy and lactation. Reprod. Toxicol. 1994, 8, 461-475.
90. Rementeria, J.L.; Bhatt, K. Withdrawal symptoms in neonates from intrauterine exposure to diazepam. J. Pediatr. 1977, 90, 123-126.
91. Gillberg, G. "Floppy infant syndrome" and maternal diazepam. Lancet 1977, 2, 244.
92. Levy, M.; Spino, M. Neonatal withdrawal syndrome: Associated drugs and pharmacologic management. Pharmacotherapy 1993, 13, 202-211.
93. Reis, M.; Källén, B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: An update using Swedish data. Psychol. Med. 2010, 11, 1723-1733.
94. Pastuszak, A.; Schick-Boschetto, B.; Zuber C.; Feldkamp, M.; Pinelli, M.; Sihn, S.; Donnenfeld, A.; McCormack. M.; Leen-Mitchell, M.; Woodland, C.; et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993, 269, 2246-2248.
95. Chambers, C.D.; Johnson, K.A.; Dick, L.M.; Felix, R.J.; Jones, K.L. Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med. 1996, 335, 1010-1015.
96. McElhatton, P.R.; Garbis, H.M.; Eléfant, E.; Vial, T.; Bellemin, B.; Matroiacovo, P.; Arnon, J.; Rodríguez-Pinilla, E.; Schaefer, C.; Pexieder, T.; et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Sevices (ENTIS). Reprod. Toxicol. 1996, 10, 285-294.
97. Kulin, N.A.; Pastuszak, A.; Sage, S.R.; Schick-Boschetto, B.; Spivey, G.; Feldkamp, M.; Ormond, K.; Matsui, D.; Stein-Schechman, M.K.; Cook, L.; et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA 1998, 279, 609-610.
98. Sivojelesova, A.; Shuhaiber, S.; Sarkissian, L.; Einarson, A.; Koren, G. Citalopram use in pregnancy: Prospective comparative evaluation of pregnancy and fetal outcome. Am. J. Obstet. Gynecol. 2005, 193, 2004-2009.
99. Einarson, A.; Pistelli, A.; DeSantis, M.; Malm, H.; Paulus, W.D.; Panchaud, A.; Kennedy, D.; Einarson, T.R.; Koren, G. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am. J. Psych. 2008, 165, 749-752.
100. Diav-Citrin, O.; Shechtman, S.; Weinbaum, D.; Wajnberg, R.; Avgil, M.; Di Gianantonio, E.; Clementi, M.; Weber-Schoendorfer, C.; Schaefer, C.; Ornoy, A. Paroxetine and fluoxetine in pregnancy: A prospective, multicentre, controlled, observational study. Br. J. Clin. Pharmacol. 2008, 66, 695-705.
101. Einarson, A.; Choi, J.; Einarson, T.R.; Koren, G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: Results of a large prospective cohort study. Can. J. Psychiatry 2009, 54, 242-246.
102. Einarson, A.; Choi, J.; Koren, G.; Einarson, T. Outcomes of infants exposed to multiple antidepressants during pregnancy: Results of a cohort study. J. Popul. Ther. Clin. Pharmacol. 2011, 18, e390-e396.
103. Hendrick, V.; Smith, L.M.; Suri, R.; Hwang, S.; Haynes, D.; Altshuler, L. Birth outcomes after prenatal exposure to antidepressant medication. Am. J. Obstet. Gynecol. 2003, 188, 812-815.
104. Cole, J.A.; Ephross, S.A.; Cosmatos, I.S.; Walker, A.M. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol. Drug Safety 2007, 16, 1075-1085.
105. Davis, R.L.; Rubanowice, D.; McPhillips, H.; Raebel, M.A.; Andrade, S.E.; Smith, D.; Yood, M.U.; Platt, R. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol. Drug Safety 2007, 16, 1086-1094.
106. Goldstein, D.J.; Corbin, L.A.; Sundell, K.L. Effects of first-trimester fluoxetine exposure on the newborn. Obstet. Gynecol. 1997, 89, 713-718.
107. Cole, J.A.; Modell, J.G.; Haight, B.R.; Cosmatos, I.S.; Stoler, J.M.; Walker, A.M. Bupropion in pregnancy amd the prevalence of congenital malformations. Pharmacoepidemiol. Drug Safety 2006, doi:10.1002/pds.1296.
108. Simon, G.E.; Cunningham, M.L.; Davis, R.L. Outcome of prenatal antidepressant exposure. Am. J. Psychiatry 2002, 159, 2055-2061.
109. Louik, C.; Lin, A.E.; Werler, M.M.; Hernándes-Diaz, S.; Mitchell, A.A. First-trimester use of selective serotonine-reuptake inhibitors and the risk of birth defects. N. Engl. J. Med. 2007, 356, 2675-2683.
110. Alwan, S.; Reefhuis, J.; Rasmussen, S.; Olney, R.S.; Friedman, J.M. Use of selective serotonine-reuptake inhibitors in pregnancy and the risk of birth defects. N. Engl. J. Med. 2007, 356, 2684-2692.
111. Bakker, M.K.; Kerstjens-Frederikse, W.S.; Buys, C.H.C.M.; de Walle, H.E.K.; de Jong-van den Berg, L.T.W. First-trimester use of paroxetine and congenital heart defects: A population-based case-control study. Birth. Def. Res. Part A 2010, 88, 94-100.
112. Alwan, S.; Reefhuis, J.; Botto, L.D.; Rasmussen, S.A.; Correa, A.; Friedman, J.M.; National Birth Defects Prevention Study. Maternal use of bupropion and risk for congenital heart defects. Am. J. Obst. Gynecol. 2010, 203, 52. e1-52. e6.
113. Polen, K.N.D.; Rasmussen, S.A.; Riehle-Colarusso, T.; Reefhuis, J.; National Birth Defects Prevention Study. Association between reported venlafaxine use in early pregnancy and birth defects, National Birth Defects Prevention Study 1997-2007. Birth. Def. Res. Part A 2013, 97, 28-34.
114. Malm, H.; Klaukka, T.; Neuvonen, P.J. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obst. Gynecol. 2005, 106, 1289-1296.
115. Wogelius, P.; Nørgaard, M.; Gislum, M.; Pedersen, L.; Munk, E.; Mortensen, P.B.; Lipworth, L.; Sørensen, H.T. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006, 17, 701-704.
116. Bérard, A.; Ramos, É.; Rey, É.; Blais, L.; St.-André, M.; Oraichi, D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: The importance of dosage. Birth. Def. Res. Part B 2007, 80, 18-27.
117. Oberlander, T.F.; Warburton, A.; Misri, S.; Riggs, W.; Aghajanian, J.; Hertzman, C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth. Def. Res. (Part B) 2008, 83, 68-76.
118. Pedersen, L.H.; Henriksen, T.B.; Vestergaard, M.; Olsen, J.; Beck, B.H. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: Population based cohort study. BMJ 2009, doi:10.1136/bmjb3569.
119. Kornum, J.B.; Nielsen, R.B.; Pedersen, L.; Mortensen, P.B.; Nørgaard, M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: Updated analysis. Clin. Epidemiol. 2010, 2, 29-36.
120. Jimenez-Solem, E.; Andersen, J.T.; Petersen, M.; Broedbaek, K.; Jensen, J.K.; Alzal, S.; Gislason, G.H.; Torp-Pedersen, C.; Poulsen, H.E. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: A nationwide cohort study. BMJ Open 2012, 2, e001148.
121. Ericson, A.; Källén, B.; Wiholm, B.-E. Delivery outcome after the use of antidepressants in early pregnancy. Eur. J. Clin. Pharmacol. 1999, 55, 503-508.
122. Källén, B. Fluoxetine use in early pregnancy. Birth. Def. Res. Part B 2004, 71, 395-396.
123. Källén, B.A.J.; Otterblad Olausson, P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth. Def. Res. Part A 2007, 79, 301-308.
124. Simon, G.E.; Cunningham, M.L.; Davis, R.L. Outcomes of prenatal antidepressant exposure. Am. J. Psychiatry 2002, 159, 2055-2061.
125. Costei, A.M.; Kozer, E.; Ho, T.; Ito, S.; Koren, G. Perinatal outcome following third trimester exposure to paroxetine. Arch. Pediatr. Adolesc. Med. 1997, 156, 1129-1132.
126. Källén, B. Neonatal characteristics after maternal use of antidepressants in late pregnancy. Arch. Pediatr. Adolesc. Med. 2004, 158, 312-316.
127. Oberlander, T.F.; Warburton, W.; Misri, S.; Aghajanian, J.; Hertzman, C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch. Gen. Psychiatry 2006, 63, 898-906.
128. Oberlander, T.F.; Warburton, W.; Misri, S.; Aghajanian, J.; Hertzman, C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: Populationbased study. Br. J. Psychiatry 2008, 192, 338-343.
129. Suri, R.; Altshuler, L.; Hellemann, G.; Burt, V.K.; Aquino, A.; Mintz, J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am. J. Psychiatry 2007, 164, 1206-1213.
130. Andersson, L.; Sundström-Poromaa, I.; Wulff, M.; Åström, M.; Bixo, M. Neonatal outcome following maternal antenatal depression and anxiety: A population-based study. Am. J. Epidemiol. 2004, 159, 872-881.
131. Hayes, R.M.; Wu, P.; Shelton, R.C.; Cooper, W.O.; Dupont, W.D.; Mitchel, E.; Hartert, T.V. Maternal antidepressant use and adverse outcomes: A cohort study of 228,876 pregnancies. Am. J. Obstet. Gynecol. 2012, 207, 49. e1-49. e9.
132. Chambers, C.D.; Hernandez-Diaz, S.; van Marter, L.J.; Werler, M.M.; Louik, C.; Jones, K.L.; Mitchell, A.A. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med. 2006, 354, 579-589.
133. Källén, B; Otterblad Olausson, P. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Safety 2008, 17, 801-806.
134. Kieler, H.; Artama, M.; Engeland, A.; Ericsson, Ö.; Furu, K.; Gissler, M.; Nielsen, R.B.; Nørgaard, M.; Stephansson, O.; Valdimarsdottir, U.; et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn; population based cohort study from five Nordic countries. BMJ 2011, 344, d8012.
135. Dubnov-Raz, G.; Juurlink, D.N.; Fogelman, R.; Merlob, P.; Ito, S.; Koren, G.; Finkelstein, Y. Antenatal use of selective serotonin. re-uptake inhibitors and QT interval prolongation in newborns. Pediatrics 2008, 122, e710.
136. Toh, S.; Mitchell, A.A.; Louik, C.; Werler, M.M.; Chambers, C.D.; Hernandez-Diaz, S. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am. J. Psychiatry 2009, 168, 320-328.
137. Palmsten, K.; Hernández-Diaz, S.; Huybrechts, K.A.; Williams, P.L.; Michels, K.B.; Achtyes, E.D.; Mogun, H.; Setogushi, S. Use of antidepressants near delivery and risk of postpartum hemorrhage: Cohort study of low income women in the United States. BMJ 2013, 347, f4877.
138. Ladhani, N.N.N.; Shah, P.S.; Murphy, K.E. Prenatal amphetamine exposure and birth outcomes: A systematic review and metaanalysis. Am. J. Obstet. Gynecol. 2011, 205, 219. e1-219. e7.
139. Debooy, V.D.; Seshia, M.M.; Tenenbein, M.; Casiro, O.G. Intravenous pentazocine and methylphenidate abuse during pregnancy. Maternal lifestyle and infant outcome. Am. J. Dis. Child. 1993, 147, 1062-1065.
140. Dideriksen, D.; Pottegård, A.; Hallas, J.; Aagaard, L.; Damkier, P. First trimester in utero exposure to methylphenidate. Basic Clin. Pharmacol. Toxicol. 2012, 112, 73-76.
141. Morales-Suárez-Varela, M.M.; Bille, C.; Christensen, K.; Olsen, J. Smoking habits, nicotine use, and congenital malformations. Obstet. Gynecol. 2006, 107, 51-57.
142. Gaither, K.; Hubor, L.R.B.; Thompson, M.E.; Huet-Hudson, Y.M. Does the use of nicotine replacement therapy during pregnancy affect pregnancy outcomes? Matern. Child Health J. 2009, 13, 427-504.
143. Strandberg-Larsen, K.; Tinggaard, M.; Nybi Andersen, A.-M.; Ilsen, J.; Grønbæk, M. Use of nicotine replacement therapy during pregnancy and stillbirth: A cohort study. BJOG 2008, 115, 1405-1410.
144. Pollak, K.I.; Chicken, C.A.; Lipkus, J.M.; Lyna, P.; Swamy, G.K.; Fletch, P.K.; Peterson, B.L.; Heine Brouwer, R.J.N.; Fish, L.; Myeers, E. Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. Am. J. Prev. Med. 2007, 33, 297-305.
145. Lacroix, I.; Berrebi, A.; Garipuy, D.; Schmitt, L.; Hammou, Y.; Chaumerliac, C.; Lapeyre-Mestre, M.; Montastruc, J.L.; Damase-Michel, C. Buphrenorphine versus methadone in pregnant opioid-dependent women: A prospective multicenter study. Eur. J. Clin. Pharmacol. 2011, 67, 1053-1059.
146. Liu, A.J.; Jones, M.P.; Murray, H.; Cook, C.M.; Nanan, R. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. Aust. N. Z. Obstet. Gynecol. 2010, 50, 253-258.
147. Greig, E.; Ash, A.; Douiri, A. Maternal and neonatal outcomes following methadone substitution during pregnancy. Arch. Gynecol. Obstet. 2012, 286, 843-851.
148. Minozzi, S.; Amato, L.; Vecchi, S.; Davoli, M. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev 2008, CD06318. doi:10.1002/4651858.CD06318.pub2.
149. Cleary, B.J.; Donnelly, J.M.; Strawbridge, J.D.; Gallagher, P.J.; Fahey, T.; White, M.J.; Murphy, D.J. Methadone and perinatal outcomes: A retrospective cohort study. Am. J. Obst. Gynecol. 2011, 204, 139. e1-139. e9.
150. Coyle, M.G.; Salisbury, A.L.; Lester, B.M.; Jones, H.E.; Lin, H.; Graf-Rohrmeister, K.; Fischer, G. Neonatal neurobehavior effects following buphrenorphine versus metadone exposure. Addiction 2012, 107 (Suppl. 1), 63-73.
151. Reis, M.; Källén, B. Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: Risk of relatively severe congenital malformations or cardiac defects. A register study. BMJ Open 2013, doi:10.1136/bmjopen-2012-002166.
152. Cleary, B.J.; Eogan, M.; O'Connell, M.P.O.; Fahey, T.; Gallagher, P.J.; Clarke, T.; White, M.J.; McDermott, C.; O'Sullivan, A.; Carmody, D.; et al. Methadone and perinatal outcomes: A prospective cohort study. Addiction 2012, 107, 1482-1492.
153. Knopik, V.S. Maternal smoking during pregnancy and child outcomes: Real or spurious effect? Dev. Neuropsychol. 2009, 34, 1-36.
154. Thapar, A.; Rice, F.; Hay, D.; Bolvin, J.; Langley, K.; van den Bree, M.; Rutter, M.; Harold, G. Prenatal smoking might not cause attention-deficit/hyperactivity disorder: Evidence from a novel design. Biol. Psychiatry 2009, 66, 722-727.
155. Streissguth, A.P. Maternal Alcoholism and the Outcome of Pregnancy: A Review of the Fetal Alcohol Syndrome. In Alcoholism Problems in Women and Children; Greenblatt, M. and Schuckit, M.A., Eds.; Seminars in Psychiatry: Grune & Stratton, New York, NY, USA, 1976; Chapter 12, pp. 251-274.
156. Eriksson, M.; Jonsson, B.; Zetterström, R. Children of mothers abusing amphetamine: Head circumference during infancy and psychosocial development until 14 years of age. Acta Paediatr. 2000, 89, 1474-1478.
157. Singer, L.T.; Moore, D.G.; Fulton, S.; Goodwin, J.; Turner, J.J.; Min, M.O.; Parrott, A.C. Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy. Neurotoxicol. Teratol. 2012, 34, 303-310.
158. LaGasse, L.L.; Derauf, C.; Smith, L.M.; Newman, E.; Shah, R.; Neal, C.; Arria, A.; Huestis, M.A.; Della Grotta, S.; Lin, H.; et al. Prenatal methamphethamine exposure and childhood behavior problems at 3 and 5 years of age. Pediatrics 2012, 129, 681-688.
159. Shah, R.; Diaz, S.D.; Arria, A.; LaGasse, L.L.; Derauf, C.; Newman, E.; Smith, L.M.; Huestis, M.A.; Haning, W.; Strauss, A.; et al. Prenatal methamphetamine exposure and shortterm maternal and infant medical outcomes. Am. J. Perinatol. 2012, 29, 391-400.
160. Marmorstein, N.R.; Iacono, W.G.; McGue, M. Alcohol and illicit drug dependence among parents: Associations with offspring externalizing disorders. Psychol. Med. 2009, 39, 149-155.
161. Bromley, R.L.; Mawer, G.; Love, J.; Kelly, J.; Purdy, L.; McEwan, L.; Briggs, M.; Clayton-Smith, J.; Shi, X.; Baker, G.A. Liverpool and Manchester Neurodevelopment Group (LMNDG). Early cognitive development in children born to women with epilepsy: A prospective report. Epilepsia 2010, 51, 2058-2065.
162. Nadebaum, C.; Anderson, V.A.; Vajda, F.; Reutens, D.C.; Barton, S.; Wood, A.G. Language skills of shool-aged children prenatally exposed to antiepileptic drugs. Neurology 2011, 76, 719-726.
163. Meador, K.J.; Baker, G.A.; Browning, N.; Cohen, M.J.; Clayton-Smith, J.; Kalaylian, L.A.; Kanner, A.; Liporace, J.D.; Pennell, P. B; Privitera, M.; et al. Foetal antiepilpeitc drug exposure and verbral versus non-verbal abilities at three years of age. Brain 2011, 134, 396-404.
164. Meador, K.J.; Baker, G.A.; Browning, N.; Cohen, M.J.; Bromley, R.L.; Clayton-Smith, J.; Kalaylian, L.A.; Kanner, A.; Liporace, J.D.; Pennell, P.B.; et al. Effect of fetal antiepileptic drug exposre: Outcomes at age 4.5 years. Neurology 2012, 78, 1207-1214.
165. Banach, R.; Boskovic, R.; Einarson, T.; Koren, G. Long-term development outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: A meta-analysis of cohorts studied. Drug. Saf. 2010, 33, 73-79.
166. Forsberg, L.; Wide, K.; Källén, B. School performance at age 16 in children exposed to antiepilpetic drugs in utero-A population-based study. Epilepsia 2011, 52, 364-369.
167. Christensen, J.; Grønborg, T.K.; Sørensen, M.J.; Schendel, D.; Parner, E.T.; Pedersen, L.H.; Vestergaard, M. Prenatal valproat exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013, 309, 1696-1703.
168. Nulman, I.; Rovet J.; Stewart, D.E.; Wolpin, J.; Gardner, H.A.; Theis, J.G.W.; Kulin, N.; Koren, G. Neurodevelopment of children exposed in utero to antidepressant drugs. N. Engl. J. Med. 1997, 336, 258-262.
169. Oberlander, T.F.; Reebye, P.; Misri, S.; Papsdorf, M.; Kim, J.; Grunau, R.E. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch. Pediatr. Adolesc. Med. 2007, 161, 22-29.
170. Hadjukhani, N. Serotonin, pregnancy and increased autism prevalence: Is there a link? Med. Hypothes. 2010, 74, 880-883.
171. Harrington, R.A.; Lee, L.C.; Crum, R.M.; Simmerman, A.W.; Hertz-Picciotto, I. Serotonin hypothesis of autism: Implications for selective serotonin inhibitor use during pregnancy. Autism Res. 2013, doi:10.1002/aur.1288.
172. Croen, L.A.; Grether, J.K.; Yostrida, C.K.; Odoui, R.; Hendrick, V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch. Gen. Psychiatry 2011, 68, 1104-1112.
173. Figueroa, R. Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. J. Dev. Behav. Pediatr. 2010, 31, 641-648.
174. Pedersen, L.H.; Henriksen, T.B.; Olsen, J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010, 125, e600-e608.